

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3344149

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	AIMM THERAPEUTICS BV	11/13/2009
RECEIVING PARTY DATA		
Name:	MEDIMMUNE LIMITED	
Street Address:	MILSTEIN BUILDING, GRANTA PARK	
City:	CAMBRIDGE	
State/Country:	UNITED KINGDOM	
Postal Code:	CB21 6GH	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14026182
CORRESPONDENCE DATA		
Fax Number:	(612)305-1228	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	612-305-1220	
Email:	DMOROZ@MRGIPLAW.COM	
Correspondent Name:	NANCY A. JOHNSON	
Address Line 1:	111 THIRD AVENUE SOUTH	
Address Line 2:	MILL PLACE, SUITE 350	
Address Line 4:	MINNEAPOLIS, MINNESOTA 55401	
ATTORNEY DOCKET NUMBER:	490.00010102	
NAME OF SUBMITTER:	NANCY A. JOHNSON	
SIGNATURE:	/Nancy A. Johnson/	
DATE SIGNED:	05/07/2015	
Total Attachments: 6		
source=Assignment - AIMM to MedImmune Limited#page1.tif		
source=Assignment - AIMM to MedImmune Limited#page2.tif		
source=Assignment - AIMM to MedImmune Limited#page3.tif		
source=Assignment - AIMM to MedImmune Limited#page4.tif		
source=Assignment - AIMM to MedImmune Limited#page5.tif		

Private & Confidential

13 November 2009

2017222/PCD/JVR

DATED 13 November 2009

AIMM THERAPEUTICS BY (1)

and

MEDIIMMUNE LIMITED (2)

PATENT ASSIGNMENT

50082012 M 2224541 / 1

PATENT
REEL: 035590 FRAME: 0124

CONTENTS

Clause	Heading	Page
1	Definitions	1
2	Assignment	1
3	Further Assurance	2
4	Applicable Law and Jurisdiction	2

THIS ASSIGNMENT is made on November 2009

BETWEEN

- (1) AIMM Therapeutics BV a body corporate organised and existing under the laws of the Netherlands and having a place of business at Melbergdreef 45, 1105 BA Amsterdam, the Netherlands (the "Assignor"); and
- (2) Medimmune Limited a body corporate organised and existing under the laws of the England and having a place of business at Milstein Building, Grant Park, Cambridge, CB21 6GH (the "Assignee").

BACKGROUND:

- (A) The Assignor is the proprietor and beneficial owner of the Patents.
- (B) Under Clause 2.1.(a) of the License Agreement dated 6th November 2009 (the "License Agreement") the Assignor has agreed to assign the Patents to the Assignee on the terms set out below.

AGREEMENT:

The parties AGREE as follows:

1 Definitions

In this Assignment unless the context otherwise requires:

"Patents" means those patent applications listed in Schedule 1, as well as any patent registrations ensuing there from and any applicable priority rights.

2 Assignment

- 2.1 In part consideration of the sums set out in Section 4.1.1 of the License Agreement, the Assignor hereby assigns and transfers to the Assignee, which transfer and assignment is hereby accepted by the Assignee, free from all encumbrances, charges, liens or similar rights or other third party rights all right, title and interest in the Patents together with all rights of action, remedies, powers and benefits.

relating to any of the Patents including the right to sue for damages for infringement before the date of this Assignment.

3 Further Assurance

3.1 The Assignor undertakes that, at the request of the Assignee, it will do all acts and things (including, without limitation, making declarations and oaths) and execute all documents that may be reasonably necessary under the law of any country for completing and registering the transfer to the Assignee of the full right, title and interest to any of the rights assigned by Clause 2 of this deed.

3.2 At the request of the Assignee, the Assignor shall provide all reasonable assistance to the Assignee which may be necessary in connection with bringing or defending any proceedings relating to any of the rights assigned or transferred by Clause 2 of this deed, and in accordance with Clause 5 of the License Agreement.

4 Applicable Law and Jurisdiction

4.1 This Assignment and any dispute or claim arising out of or in connection with it shall be governed by and construed in accordance with the laws of the Netherlands, unless mandatory foreign law is applicable, and all disputes and claims arising out of or relating to this Assignment shall be subject to the exclusive jurisdiction of the Courts of the Netherlands to which the parties irrevocably submit.


IN WITNESS of the above the Assignor and Assignee have signed this Assignment on the date written at the head of this Agreement.

Schedule 1


WO 2008/147196 "RSV Specific Binding Molecules and means for producing them"
filed May 30, 2008.

Patent filed on October 6, 2009 covering AM22 number - PCT/NL2009/050599.


MEDIMMUNE LIMITED

By 
Name: JANE OSBORN
Title: SITE LEADER & VP
RESEARCH MEDIMMUNE
CAMBRIDGE

AIMM THERAPEUTICS BV.

By 
Name: Herger Spits
Title: Managing Director

and

By 
On behalf of Willem J. van Oort
Life Technology Management B.V.

Name: Cour De Guillaume B.V.
Title: Solely authorised managing
director
On behalf of Cour De Guillaume B.V.

Name: W.J. van Oort
Title: Solely authorised managing
director